Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Liquidity Ratios (Summary)

Vertex Pharmaceuticals Inc., liquidity ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


An analysis of liquidity trends from March 2022 through June 2026 reveals a sustained period of contraction followed by a partial recovery. All three primary liquidity indicators exhibit a high degree of correlation, reflecting a consistent shift in the short-term asset position relative to current liabilities.

Current Ratio
The current ratio experienced a gradual decline from a peak of 4.83 in December 2022 to a trough of 2.36 in September 2025. A reversal of this trend is observed starting in December 2025, with the ratio ascending to 3.19 by June 2026.
Quick Ratio
The quick ratio mirrored the trajectory of the current ratio, decreasing from 4.46 in December 2022 to a low of 1.84 in September 2025. A subsequent recovery trend is evident in the final three quarters, with the ratio reaching 2.54 by June 2026.
Cash Ratio
The most pronounced decline occurred in the cash ratio, which fell from 3.93 in December 2022 to a minimum of 1.40 in September 2025. This indicates a significant reduction in the most liquid assets relative to short-term obligations before a recovery to 1.99 by June 2026.

Despite the substantial decrease in liquidity metrics between 2022 and late 2025, all ratios remained consistently above 1.0. This indicates that the capacity to meet short-term obligations was maintained throughout the period, while the recovery observed in 2026 suggests a strengthening of the overall liquidity position.


Current Ratio

Vertex Pharmaceuticals Inc., current ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity position of the company exhibited significant volatility over the analyzed period, characterized by an initial phase of high liquidity, a sharp contraction in mid-2024, and a subsequent gradual recovery through June 2026.

Current Assets Trend
Current assets showed a steady increase from March 31, 2022, peaking at 14.69 billion US dollars in September 2023. A substantial reduction occurred by June 30, 2024, when assets dropped to 8.94 billion US dollars. Following this trough, a consistent recovery trend was observed, with assets rising to 12.54 billion US dollars by June 30, 2026.
Current Liabilities Trend
Current liabilities followed a general upward trajectory, increasing from 2.18 billion US dollars in March 2022 to a peak of 4.47 billion US dollars in June 2025. While there was a slight decrease in the latter part of the period, liabilities remained elevated compared to the 2022 baseline, stabilizing around 3.93 billion US dollars by June 2026.
Current Ratio Analysis
The current ratio began at a very high level of 4.75 in March 2022, maintaining levels above 4.0 through September 2023. A notable decline began in early 2024, reaching a low of 2.36 by September 30, 2025. This compression was driven by the simultaneous decrease in current assets and the increase in current liabilities. However, the ratio improved during the final three quarters of the sequence, ending at 3.19 in June 2026.

Despite the downward shift from the initial peaks, the current ratio remained well above 2.0 throughout the entire period. This indicates that the company maintained a substantial cushion of liquid assets to cover its short-term obligations, signifying a strong and sustainable liquidity position even during the period of asset contraction.


Quick Ratio

Vertex Pharmaceuticals Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Cash and cash equivalents
Marketable securities
Accounts receivable, net
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity profile of the organization exhibits a general downward trend in the quick ratio over the analyzed period, moving from a position of exceptionally high liquidity to a more moderate, albeit stable, level. While the quick ratio remains well above 1.0, indicating a consistent ability to meet short-term obligations without relying on inventory, there is a marked shift in the composition of the balance sheet between 2022 and 2026.

Total Quick Assets Trend
Quick assets experienced an initial growth phase, peaking at 13,466,900 thousand US$ in September 2023. This was followed by a significant contraction in the second quarter of 2024, where assets dropped to 7,451,600 thousand US$. From June 2024 through June 2026, a gradual recovery phase is observed, with quick assets steadily increasing to reach 9,986,700 thousand US$ by the end of the period.
Current Liabilities Evolution
Current liabilities demonstrate a sustained upward trajectory for the majority of the period. Obligations rose from 2,180,200 thousand US$ in March 2022 to a peak of 4,475,300 thousand US$ in June 2025. Following this peak, liabilities stabilized and slightly declined, ending the period at 3,937,900 thousand US$ in June 2026.
Quick Ratio Performance
The quick ratio began at a very high level of 4.37 in March 2022, peaking at 4.46 in December 2022. A consistent decline followed, characterized by a sharp drop between March 2024 (3.15) and June 2024 (2.10). The ratio reached its lowest point of 1.84 in September 2025. However, the final three quarters show a recovery trend, with the ratio climbing back to 2.54 by June 2026.

The overall analysis suggests a period of significant capital reallocation or expenditure occurring in early 2024, which coincided with the sharpest decline in the quick ratio. Despite the reduction from the initial peaks, the organization maintains a strong liquidity cushion, as the quick ratio remains consistently above 1.80 throughout the entire period, ensuring sufficient liquid assets to cover current liabilities.


Cash Ratio

Vertex Pharmaceuticals Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Cash and cash equivalents
Marketable securities
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


An analysis of the liquidity position from March 31, 2022, to June 30, 2026, reveals a significant shift in the company's cash management strategy and overall liquidity profile. The period is characterized by an initial phase of high liquidity accumulation, followed by a sharp contraction in cash assets in mid-2024, and a subsequent period of gradual recovery.

Total Cash Assets Trend
Cash holdings exhibited steady growth from March 2022, rising from 8.24 billion to a peak of 11.93 billion by September 30, 2023. A substantial reduction occurred between March 31, 2024, and June 30, 2024, where assets decreased from 10.17 billion to 5.80 billion. Following this decline, cash levels entered a recovery phase, trending upward to reach 7.85 billion by June 30, 2026.
Current Liabilities Trajectory
Current liabilities demonstrated a consistent upward trend for the first several years, increasing from 2.18 billion in March 2022 to a peak of 4.48 billion in June 2025. Unlike the volatility seen in cash assets, the growth in liabilities was more linear, though a slight contraction occurred toward the end of 2025, stabilizing around 3.94 billion by June 2026.
Cash Ratio Dynamics
The cash ratio, which measures the ability to cover short-term obligations with the most liquid assets, peaked at 3.93 in December 2022. A sustained decline followed, accelerating sharply in June 2024 to 1.63. The ratio reached its lowest point of 1.40 in September 2025. Since that low, the ratio has improved steadily, closing at 1.99 in June 2026.
Liquidity Assessment
Despite the volatility and the significant drop in the cash ratio between 2022 and 2025, the company maintained a cash ratio above 1.0 throughout the entire reporting period. This indicates that the company consistently held sufficient cash and cash equivalents to satisfy all current liabilities without relying on the sale of inventory or the collection of receivables.